14 Nov 2017 11:30
REDX PHARMA PLC
("Redx" or "the Company")
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS
DISCHARGING MANAGERIAL RESPONSIBILITIES
Alderley Park, November 14 2017- Redx Pharma (AIM:REDX), the drug discovery and development company, announces that is has been notified that Iain Ross, Executive Chairman, has today acquired 348,000 Redx ordinary shares at a price of 18.036 pence per share. Following this, Mr Ross will hold 348,000 ordinary shares in the Company, representing 0.28 per cent. of the issued share capital.
Mr Ross purchased the shares through his self-invested personal pension (SIPP) and the notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further details:
1 | Details of the person discharging managerial responsibilities/person closely associated | |
a) | Name | Iain Ross |
2 | Reason for the notification | |
a) | Position/status | Executive Chairman |
b) | Initial notification/ Amendment | Initial notification |
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |
a) | Name | Redx Pharma plc |
b) | LEI | 213800HMS4EBXO589Y37 |
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |
a) | Description of the financial instrument, type of instrument Identification code | Ordinary shares of 1 pence
ISIN: GB00BSNB6S51 |
b) | Nature of the transaction | Purchase of shares through self-invested personal pension (SIPP) |
c) | Price(s) and volume(s) | 348,000 ordinary shares at a price of 18.036 pence per share |
d) | Aggregated information - Aggregated volume - Price
| N/A |
e) | Date of the transaction | 14 November 2017 |
f) | Place of the transaction | London Stock Exchange, AIM (XLON) |
For further information, please contact:
Redx Pharma Plc | T: +44 1625 469 918 |
Iain Ross, Executive Chairman |
|
Cantor Fitzgerald Europe (Nominated Advisor & Broker) | T: +44 20 7894 7000 |
Phil Davies |
|
|
|
WG Partners LLP (Joint Broker) | T: +44 20 3705 9330 |
Claes Spång/ Chris Lee/ David Wilson |
|
|
|
FTI Consulting | T: +44 20 3727 1000 |
Simon Conway/Stephanie Cuthbert |
|
About Redx Pharma Plc
Redx is a UK biotechnology company whose shares are traded on AIM (AIM:REDX). Redx is focused on creating and developing first, or potentially best in class drugs, in specific areas of oncology and fibrosis that address significant unmet medical need. Redx has a significant in-house discovery team with proven world-class chemistry capabilities.